European CHMP recommends approval of relugolix/estradiol/norethisterone acetate (Ryeqo) for treatment of symptoms of uterine fibroids

Ryeqo is approved for treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. Ryeqo will be available as 40-mg / 1-mg / 0.5-mg film-coated tablets.

Source:

European Medicines Agency